Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: a post-hoc causal inference model using the AMARCAND2 study

Sébastien Bailly 1 Olivier Leroy 2 Elie Azoulay 3 Philippe Montravers 4 Jean-Michel Constantin 5 Hervé Dupont 6 Didier Guillemot 7 Olivier Lortholary 8, 9 Jean-Paul Mira 10 Pierre-François Perrigault 11 Jean-Pierre Gangneux 12 Jean-Francois Timsit 1, 13
1 IAME - Infection, Antimicrobiens, Modélisation, Evolution
2 Hôpital Chatiliez
3 Medical ICU
4 Service d'anesthésie - réanimation chirurgicale
5 Département anesthésie et réanimation
6 CHU Amiens-Picardie - Centre hospitalier universitaire d'Amiens
7 B2PHI - Biostatistique, Biomathématique, Pharmacoépidémiologie et Maladies Infectieuses
8 Centre d'infectiologie Necker-Pasteur [CHU Necker]
9 CNRMA - Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire
10 Service de médecine d'urgence [CHU Cochin]
11 CHU Montpellier
12 CHU Pontchaillou [Rennes]
13 Hôpital Bichat - Claude Bernard
Abstract : Objective: guidelines recommend first-line systemic antifungal therapy (SAT) with echinocandins in invasive candidiasis (IC), especially in critically ill patients. This study aimed at assessing the impact of echinocandins compared to azoles as initial SAT on the 28-day prognosis in adult ICU patients. Methods: From the prospective multicenter AmarCAND2 cohort (835 patients), we selected those with documented IC and treated with echinocandins (ECH) or azoles (AZO). The average causal effect of echinocandins on 28-day mortality was assessed using an inverse probability of treatment weight (IPTW) estimator. Results: 397 patients were selected, treated with echinocandins (242 patients, 61%) or azoles (155 patients, 39%); septic shock: 179 patients (45%). The median SAPSII was higher in the ECH group (48 [35; 62] vs. 43 [31; 58], p = 0.01). Crude mortality was 34% (ECH group) vs. 25% (AZO group). After adjustment on baseline confounders, no significant association emerged between initial SAT with echinocandins and 28-day mortality (HR: 0.95; 95% CI: [0.60; 1.49]; p = 0.82). However, echinocandin tended to benefit patients with septic shock (HR: 0.46 [0.19; 1.07]; p = 0.07). Conclusion: Patients who received echinocandins were more severely ill. Echinocandin use was associated with a non-significant 7% decrease of 28-day mortality and a trend to a beneficial effect for patient with septic shock.
Type de document :
Article dans une revue
Journal of Infection, WB Saunders, 2017, 74 (4), pp.408-417. 〈10.1016/j.jinf.2016.12.016〉
Liste complète des métadonnées

Littérature citée [28 références]  Voir  Masquer  Télécharger
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01632852
Contributeur : Laurent Jonchère <>
Soumis le : vendredi 10 novembre 2017 - 16:24:51
Dernière modification le : jeudi 15 novembre 2018 - 20:27:38
Document(s) archivé(s) le : dimanche 11 février 2018 - 14:38:16

Fichier

Bailly et al. - Impact of echi...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

UNIV-PARIS5 | PASTEUR | UVSQ | USPC | UNIV-PARIS13 | IAME | UNIV-PARIS-SACLAY | UNIV-RENNES

Citation

Sébastien Bailly, Olivier Leroy, Elie Azoulay, Philippe Montravers, Jean-Michel Constantin, et al.. Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: a post-hoc causal inference model using the AMARCAND2 study. Journal of Infection, WB Saunders, 2017, 74 (4), pp.408-417. 〈10.1016/j.jinf.2016.12.016〉. 〈hal-01632852〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

428

Téléchargements de fichiers

64